Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

29 Apr 2016 17:30

RNS Number : 9044W
AstraZeneca PLC
29 April 2016
 

ASTRAZENECA PLC - ANNUAL GENERAL MEETING 2016

 

Results of Annual General Meeting held on 29 April 2016

 

AstraZeneca PLC announced the results of the voting at its Annual General Meeting today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 - 8 were passed as ordinary resolutions and resolutions 9 - 11 were passed as special resolutions.

 

 

RESOLUTION

VOTES FOR

% OF VOTES CAST

VOTES AGAINST

% OF VOTES CAST

VOTES CAST IN TOTAL

TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL

VOTES WITHHELD

1

To receive the Company's Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2015

 

924,514,473

99.61

3,665,459

0.39

928,179,932

73.40%

8,998,621

2

To confirm dividends

 

933,191,043

99.69

2,915,972

0.31

936,107,015

74.03%

1,071,537

3

To re-appoint KPMG LLP, London as Auditor

 

929,918,594

99.56

4,151,154

0.44

934,069,748

73.87%

3,108,804

4

To authorise the Directors to agree the remuneration of the Auditor

 

934,984,319

99.89

988,556

0.11

935,972,875

74.02%

1,204,865

5a

To re-elect Leif Johansson as a Director

 

861,678,834

94.69

48,321,545

5.31

910,000,379

71.96%

27,177,942

5b

To re-elect Pascal Soriot as a Director

 

935,167,473

99.93

697,471

0.07

935,864,944

74.01%

1,342,796

5c

To re-elect Marc Dunoyer as a Director

 

931,875,086

99.58

3,920,615

0.42

935,795,701

74.00%

1,380,982

5d

To re-elect Cori Bargmann as a Director

 

935,157,654

99.93

635,873

0.07

935,793,527

74.00%

1,384,110

5e

To re-elect Geneviève Berger as a Director

 

935,199,102

99.93

622,099

0.07

935,821,201

74.00%

1,356,436

5f

To re-elect Bruce Burlington as a Director

 

933,026,505

99.70

2,762,355

0.30

935,788,860

74.00%

1,389,088

5g

To re-elect Ann Cairns as a Director

 

933,220,149

99.72

2,618,183

0.28

935,838,332

74.01%

1,339,989

5h

To re-elect Graham Chipchase as a Director

 

919,686,570

98.97

9,526,012

1.03

929,212,582

73.48%

7,965,366

5i

To re-elect Jean-Philippe Courtois as a Director

 

933,177,891

99.72

2,593,420

0.28

935,771,311

74.00%

1,406,637

5j

To re-elect Rudy Markham as a Director

 

923,984,532

98.74

11,766,347

1.26

935,750,879

74.00%

1,427,442

5k

To re-elect Shriti Vadera as a Director

 

927,479,182

99.11

8,287,726

0.89

935,766,908

74.00%

1,410,552

5l

To re-elect Marcus Wallenberg as a Director

 

870,828,312

95.76

38,511,577

4.24

909,339,889

71.91%

27,837,158

6

To approve the Annual Report on Remuneration for the year ended 31 December 2015

836,396,151

89.61

96,959,428

10.39

933,355,579

73.81%

3,822,290

7

To authorise limited EU political donations

 

908,106,542

97.83

20,185,176

2.17

928,291,718

73.41%

8,886,009

8

To authorise the Directors to allot shares

 

849,809,843

90.97

84,303,774

9.03

934,113,617

73.87%

3,064,122

9

To authorise the Directors to disapply pre-emption rights

 

922,425,478

98.82

11,009,374

1.18

933,434,852

73.82%

3,742,888

10

To authorise the Company to purchase its own shares

 

926,166,577

98.96

9,722,078

1.04

935,888,655

74.01%

1,289,613

11

To reduce the notice period for general meetings

 

829,946,353

88.85

104,116,202

11.15

934,062,555

73.87%

3,115,081

 

 

 

Issued capital

As at 27 April 2016, the number of issued shares of the Company was 1,264,542,488 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

 

 

A C N Kemp

Company Secretary

29 April 2016

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGPGUGACUPQGAB
Date   Source Headline
1st Apr 20193:00 pmRNSTotal Voting Rights
1st Apr 20197:00 amRNSSelumetinib gets Breakthrough Therapy Designation
29th Mar 20195:15 pmRNSResults of Placing
29th Mar 20197:00 amRNSProposed placing of new ordinary shares
29th Mar 20197:00 amRNSAZ and Daiichi Sankyo enter collaboration in novel
27th Mar 20197:00 amRNSForxiga approved in Japan for type-1 diabetes
25th Mar 20197:00 amRNSForxiga approved in Europe for type-1 diabetes
18th Mar 20197:00 amRNSUS FDA grants saracatinib ODD for IPF
14th Mar 201912:00 pmRNSNotice of AGM
12th Mar 201912:00 pmRNSDirector/PDMR Shareholding
6th Mar 20197:00 amRNSFiling of Form 20-F with SEC
5th Mar 201911:00 amRNSAnnual Financial Report
4th Mar 20194:04 pmRNSHolding(s) in Company
1st Mar 20193:00 pmRNSTotal Voting Rights
1st Mar 20191:45 pmRNSLynparza receives positive EU CHMP opinion
26th Feb 20197:00 amRNSLynparza significantly delayed disease progression
25th Feb 20197:00 amRNSBrilinta's PhIII THEMIS trial met primary endpoint
14th Feb 20197:00 amRNSAstraZeneca Full-Year and Q4 2018 Results
6th Feb 20197:00 amRNSUS FDA grants Fasenra Orphan Drug Designation
5th Feb 20197:05 amRNSUS FDA grants Breakthrough Therapy Designation
5th Feb 20197:00 amRNSEMA grants PRIME eligibility for MEDI8897
1st Feb 20193:00 pmRNSTotal Voting Rights
1st Feb 20191:17 pmRNSForxiga receives positive EU CHMP opinion
25th Jan 20192:00 pmRNSCompletion of divestment of US Synagis rights
7th Jan 20191:00 pmRNSAstraZeneca announces organisational changes
2nd Jan 20193:00 pmRNSTotal Voting Rights
20th Dec 20181:47 pmRNSBevespi Aerosphere approved in the EU for COPD
20th Dec 20187:05 amRNSLynparza meets primary endpoint in SOLO-3 trial
20th Dec 20187:00 amRNSPhase III ROCKIES and OLYMPUS roxadustat trials
19th Dec 20186:31 pmRNSFDA approves Lynparza as 1L maintenance therapy
18th Dec 20189:09 amRNSRoxadustat approved in China for the treatment of
14th Dec 20187:00 amRNSDirectorate Change
7th Dec 20187:00 amRNSUpdate on the Phase III EAGLE trial of Imfinzi
6th Dec 20187:00 amRNSDivestment of rights to Covis completed
4th Dec 20183:00 pmRNSDirector/PDMR Shareholding
3rd Dec 20184:00 pmRNSBlock listing Interim Review
3rd Dec 20184:00 pmRNSTotal Voting Rights
3rd Dec 20187:00 amRNSGrünenthal Agreement for Nexium, Vimovo Completed
26th Nov 20187:00 amRNSUS FDA grants Fasenra ODD for EGPA
16th Nov 20187:00 amRNSAstraZeneca provides update on Phase III MYSTIC
13th Nov 20187:00 amRNSAstraZeneca to divest US Synagis rights to Sobi
12th Nov 20187:05 amRNSUS FDA accepts regulatory submission for Lynparza
12th Nov 20187:00 amRNSFarxiga significantly reduced hospitalisation for
8th Nov 20187:00 amRNSAZN: Year-to-Date and Q3 2018 Results
6th Nov 20187:00 amRNSDivestment of rights to Covis Pharma
1st Nov 20183:00 pmRNSTotal Voting Rights
31st Oct 20189:45 amRNSAdditional financial information-Grünenthal deal
30th Oct 20187:00 amRNSGrünenthal Agreement for rights to Nexium, Vimovo
23rd Oct 20187:00 amRNSAstraZeneca Extends Innate Pharma Collaboration
22nd Oct 20187:00 amRNSLynparza shows 70% reduction in PFS ovarian cancer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.